医学
连续血糖监测
低血糖
血糖性
重症监护室
重症监护医学
大流行
远程病人监护
糖尿病
注意事项
持续监测
2019年冠状病毒病(COVID-19)
血糖自我监测
医疗保健
医疗急救
急诊医学
护理部
疾病
内科学
运营管理
传染病(医学专业)
经济
内分泌学
经济增长
作者
Lizda Guerrero-Arroyo,Eileen R Faulds,Mireya C. Perez-Guzman,Georgia Davis,Kathleen Dungan,Francisco J. Pasquel
标识
DOI:10.1177/19322968231169522
摘要
Traditionally, the care of critically ill patients with diabetes or stress hyperglycemia in the intensive care unit (ICU) demands the use of continuous intravenous insulin (CII) therapy to achieve narrow glycemic targets. To reduce the risk of iatrogenic hypoglycemia and to achieve glycemic targets during CII, healthcare providers (HCP) rely on hourly point-of-care (POC) arterial or capillary glucose tests obtained with glucose monitors. The burden of this approach, however, was evident during the beginning of the pandemic when the immediate reduction in close contact interactions between HCP and patients with COVID-19 was necessary to avoid potentially life-threatening exposures. Taking advantage of the advancements in current diabetes technologies, including continuous glucose monitoring (CGM) devices integrated with digital health tools for remote monitoring, HCP implemented novel protocols in the ICU to care for patients with COVID-19 and hyperglycemia. We provide an overview of research conducted in the ICU setting with the use of initial CGM technology to current devices and summarize our recent experience in the ICU.
科研通智能强力驱动
Strongly Powered by AbleSci AI